| Expression pattern: |
UP |
| Associated gene: |
FGFR1, AGO2 |
| Associated microRNA: |
miR-1205 |
| Biological function: |
promotes cisplatin (DDP) resistance, colony formation, migration and invasion, and inhibits apoptosis in DDP-resistant gastric cancer cells |
| Molecular mechanism: |
ceRNA sponge mechanism: circARVCF sponges miR-1205 to elevate FGFR1 expression, thereby enhancing cisplatin resistance |
| Biological pathway or process: |
chemoresistance (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Actinomycin D / DRB Stability Assay; RNase R Treatment; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; IHC (Immunohistochemistry); Clinical Sample Validation |
| Clinical significance: |
- |
| Description: |
circARVCF is upregulated in cisplatin-resistant gastric cancer tissues/cells and promotes DDP resistance and malignant phenotypes. Mechanistically, it acts as a ceRNA by sponging miR-1205 to increase FGFR1 expression, and circARVCF knockdown improves DDP sensitivity in vitro and in a xenograft model. |
| Confidence score: |
0.8171 |